Insufficient· Insufficient EvidenceNarrative Review

Healing from Within: Regenerative Medicine in Pain Therapy.

Loffredo AJ., Chang Chien GC., Pangarkar SS.

Narrative Review on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, published in Phys Med Rehabil Clin N Am (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Phys Med Rehabil Clin N Am (2026)
Country
United States
Reported sample size
PMID
42379698
DOI
10.1016/j.pmr.2026.03.011

Abstract (original English)

This article reviews 6 categories of regenerative therapies for chronic pain, including cell-based therapies, biologics, gene therapy, exosomes, tissue engineering, and biophysical stimuli. While mesenchymal stem cells, bone marrow aspirate concentrate, and adipose-derived stem cells show promise for mild conditions like knee osteoarthritis and lateral epicondylitis, no regenerative therapy is Food and Drug Administration (FDA)-approved for chronic pain. Platelet-rich plasma and autologous conditioned serum are not FDA-approved as stand-alone treatments. Clinical guidance includes holding nonsteroidal anti-inflammatory drugs, avoiding cytotoxic anesthetics, and managing expectations. The article highlights legal risks related to biologics and stresses need for standardized protocols and high-quality trials.

What this study does not prove

  • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

There is currently not enough data to draw conclusions about benefit or risk for this topic.

How we grade evidence
HumansRegenerative MedicineChronic PainGenetic TherapyPain ManagementTissue EngineeringPlatelet-Rich Plasma

Related research